EU Commission opens antitrust probe into Sanofi flu vaccine campaign

• The investigation targets Sanofi's marketing campaign for 'Efluelda' flu vaccine, which allegedly disparaged rival CSL Seqirus's 'Fluad' vaccine, primarily in France and Germany
• Sanofi holds a dominant market position in both France and Germany, raising concerns about potential anticompetitive behavior
• The formal investigation follows unannounced raids on Sanofi offices in September, with the company stating it is confident in its compliance and will cooperate fully

EU Commission Opens Antitrust Investigation into Sanofi Flu Vaccine Marketing

The European Commission launched a formal antitrust investigation on June 26 into French pharmaceutical giant Sanofi over alleged anti-competitive practices in its flu vaccine marketing campaign. The probe focuses on whether Sanofi violated EU competition rules by conducting a misleading campaign to promote its "Efluelda" flu vaccine while disparaging a competing product, "Fluad," manufactured by CSL Seqirus.

Key Details:

The alleged misconduct primarily occurred in France and Germany, where Sanofi holds a dominant market position in the flu vaccine sector. The investigation follows unannounced raids conducted on Sanofi offices in September of the previous year.

Company Response:

Sanofi has stated it is confident in its compliance with relevant rules and regulations and committed to full cooperation with the European Commission during the investigation.

Market Implications:

This antitrust probe adds regulatory pressure on Sanofi and could have significant implications for pharmaceutical marketing practices across the EU. If found guilty of anti-competitive behavior, Sanofi could face substantial fines and be required to modify its marketing strategies. The investigation also highlights increased scrutiny from EU regulators on dominant players using potentially disparaging tactics against competitors.

The outcome could set important precedents for how pharmaceutical companies market competing products, particularly in markets where they hold dominant positions. Investors should monitor developments closely, as penalties and reputational damage could impact Sanofi's market position and financial performance in the European flu vaccine market.